Adrenomed is currently developing a new drug to significantly decrease mortality in severe sepsis. Sepsis involves an overactive inflammatory response to severe bacterial infection that can compromise vascular integrity and cause tissue edema, organ dysfunction and death. Severe sepsis accounts for 20% of all admissions to intensive care units (ICUs) and is the leading cause of death in non-cardiac ICUs. The incidence, outcome, and associated costs of care, clearly document an unmet medical need: in the USA, mortality from severe sepsis was 28.6%, or 215,000 deaths. The average costs per case were $22,100, with annual total costs of $16.7 billion. Despite tremendous improvements in hospital hygiene and sepsis therapy strategies, the incidence of sepsis has doubled in the past 10 years and is still increasing.
Adrenomed’s mission is to provide life-saving therapies in sepsis.
Recent scientific publications:
Joachim Struck, Frauke Hein, Siegmund Karasch, Andreas Bergmann Intensive Care Medicine Experimental 2013, 1:3 (29 October 2013)
Katja Wagner, Ulrich Wachter, Josef A Vogt, Angelika Scheuerle, Oscar McCook, Sandra Weber, Michael Gröger, Bettina Stahl, Michael Georgieff, Peter Möller, Andreas Bergmann, Frauke Hein, Enrico Calzia, Peter Radermacher, Florian Wagner Intensive Care Medicine Experimental 2013, 1:2 (29 October 2013)
Kox M, Pickkers P.
Intensive Care Medicine Experimental 2014, 2:1